Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | TK2 | O00142 | 9/20 | 0.40 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948846 | 0.87 | KIF11 (0.41) | KIF11HRH4TK2TK1CYP2C9 | |
| SCHEMBL5325668 | 0.83 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL27864641 | 0.82 | MAPK1 (0.44) | KIF11HRH4ALOX15CYP2C19LTB4R | |
| SCHEMBL5323607 | 0.78 | KIF11 (0.53) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL11275984 | 0.77 | KIF11 (0.74) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL5326522 | 0.76 | KIF11 (0.52) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL9542051 | 0.75 | LTB4R (0.39) | KIF11TK2TK1CYP2C9ALOX15 | |
| SCHEMBL8389233 | 0.75 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL2489713 | 0.75 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL913478 | 0.75 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090233948-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | NATIONAL INSTITUTES OF HEALTH | 2009-09-17 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1881984-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, a division of YESHIVA UNIVERSITY (US) | 2008-01-30 | — | — | EP | disclosed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006123953-A1 | INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | KIF11 2122/4885HRH4 3436/4885TK2 4/4885 |
| US-20090233948-A1 | Inhibitors of nucleoside phosphorylases and nucleosidases | PNP, MTAP, TYMP | KIF11 4265/4885HRH4 3530/4885TK2 161/4885 |
| US-20060165655-A1 | Therapeutic furopyrimidines and thienopyrimidines | DPYD, TYMP, TYMS | KIF11 2122/4885HRH4 3436/4885TK2 4/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | KIF11 2122/4885HRH4 3436/4885TK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.